Market information

Roivant Sciences Ltd

Ticker: ROIV
Exchange: NASDAQ
Country: USA

Price History

Business

Company profile

AER Insights

Illustrative slit-lamp examination instrument and anatomical eye model in an ophthalmology room.

Biotechnology & Healthcare

Roivant’s Uveitis Results Give Brepocitinib a Stronger Route to a Second Market

Two positive Phase 3 studies strengthen the case for expanding brepocitinib beyond its newly approved use in dermatomyositis. Durable disease control after steroid withdrawal supports a commercial opportunity in eye inflammation, although the higher studied dose, safety profile and established alternatives will influence its reach.

Alliance Equity ResearchOctober 21, 20267 min read

Read article

Financials

Fundamental data

Market information is supplied by TradingView and may be delayed or unavailable for certain exchanges or instruments. It does not constitute investment advice.

Alliance Equity Research Coverage

No current AER coverage

Related AER Insights are available above. This company does not currently have published AER company coverage.

Request Coverage